SCHEMBL5158384

SCHEMBL5158384

CC(C)OC(=O)CC(=O)c1cn[nH]c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACACB O00763 6/20 0.41
NOS2 P35228 1/20 0.40
TSHR P16473 2/20 0.37
ALDH1A1 P00352 2/20 0.34
HTT P42858 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
PPARG P37231 1/20 0.34
NCOA2 Q15596 1/20 0.34
NCOA1 Q15788 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
NCOA3 Q9Y6Q9 1/20 0.34
MME P08473 1/20 0.33
RECQL P46063 1/20 0.33
PIM1 P11309 1/20 0.33
PIM3 Q86V86 1/20 0.33
PIM2 Q9P1W9 1/20 0.33
ACACA Q13085 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160875 0.83 MEN1 (0.41) ACACBNOS2ALDH1A1HTTMEN1
SCHEMBL5162787 0.79 KMT2A (0.53) ACACBTSHRALDH1A1MEN1KMT2A
SCHEMBL19100007 0.78 CA12 (0.48) ACACBNOS2ALDH1A1HTTMEN1
SCHEMBL5160415 0.77 ALDH1A1 (0.35) ACACBNOS2ALDH1A1HTT
SCHEMBL5160505 0.77 HCAR2 (0.39) ACACBTSHRALDH1A1MEN1KMT2A
SCHEMBL23480570 0.76 TDP1 (0.51) ACACBNOS2ALDH1A1HTT
SCHEMBL20797184 0.75 ALDH1A1 (0.38) ACACBNOS2ALDH1A1HTTMEN1
SCHEMBL5161535 0.75 ALDH1A1 (0.39) ACACBNOS2ALDH1A1HTTMME
SCHEMBL5159969 0.74 TSHR (0.40) ACACBTSHRALDH1A1HTTMEN1
SCHEMBL5178020 0.74 NOS2 (0.38) ACACBNOS2ALDH1A1HTTMME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO ACACB 76/4885NOS2 3219/4885TSHR 4474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.